Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Clinical trial NCT00908180 · UNKNOWN
Trial details
- NCT number
- NCT00908180
- Sponsor
- Cancer Research UK
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2009-07-01
- Primary completion
- 2014-07-01
- Enrollment
- 47
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.